Platelet activating factor antagonists interact with GABAA receptors

Area of Science:

• Neuroscience
• Pharmacology
• Neurochemistry

Background:

• Platelet-activating factor (PAF) is a ubiquitous signaling molecule in mammals with diverse roles, including potential functions within the central nervous system.
• Triazolobenzodiazepine compounds exhibit dual activity, interacting with both the GABAA receptor and acting as PAF antagonists.

Purpose of the Study:

• To investigate the potential involvement of PAF antagonist activity in the central nervous system actions of triazolobenzodiazepines.
• To examine the effects of non-benzodiazepine PAF antagonists on GABAA receptor binding and function.

Main Methods:

• Assessed the impact of BN 52021 (a gingkolide terpene) and BN 52115 (a dioxolane-based compound) on benzodiazepine and chloride channel binding in cortical membrane preparations.
• Measured chloride uptake into cortical synaptoneurosomes to evaluate GABAA receptor function.
• Investigated the effect of flumazenil on BN 52021-induced changes in chloride uptake.

Main Results:

• Neither BN 52021 nor BN 52115 affected benzodiazepine or chloride channel binding at the GABAA receptor.
• BN 52021 significantly enhanced chloride uptake into cortical synaptoneurosomes at a concentration of 1 microM, while BN 52115 did not.
• The enhancing effect of BN 52021 on chloride uptake was reversed by the co-administration of 1 microM flumazenil.

Conclusions:

• PAF antagonists can modulate GABAA receptor function, specifically enhancing chloride ion transport.
• The observed augmentation of GABAA receptor function by PAF antagonists occurs independently of changes in receptor binding affinity.
• These findings suggest a novel mechanism by which PAF antagonists may influence neuronal activity via GABAA receptor modulation.